Risk-directed therapy and research in neuroblastoma  by Liu, Yen-Lin et al.
Journal of the Formosan Medical Association (2014) 113, 887e889Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jfma-onl ine.comPERSPECTIVESRisk-directed therapy and research in
neuroblastoma
Yen-Lin Liu a,b,c,d, James S. Miser e, Wen-Ming Hsu f,*a Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan
b Ph.D. of Translational Medicine Program, National Taiwan University and Academia Sinica, Taipei,
Taiwan
c Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan
d Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
e College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
f Department of Surgery, National Taiwan University Hospital and National Taiwan University College
of Medicine, Taipei, TaiwanReceived 19 November 2014; accepted 21 November 2014Neuroblastoma has a heterogeneous clinical course.1 A
child with neuroblastoma may present with metastatic
disease with a high risk of recurrence, or with limited dis-
ease with a low risk of relapse, or with tumors that spon-
taneously regress or differentiate into benign tumors (a
course usually seen in infants).1 This heterogeneity prob-
ably reflects the malignant transformation of cells within
the sympatheticeadrenal lineage of the neural crest at
various stages of embryonic maturation.1 Neuroblastoma
cells may recapitulate the behavior of neurons and have
been broadly used in research into developmental neuro-
biology, neuronal differentiation, neurodegenerative dis-
ease, and cancer biology, making neuroblastoma a “model
disease” for research.2
Neuroblastoma ranks as the second most common
extracranial solid tumor in children and adolescents in
Taiwan after germ cell tumors.3 Since the implementation
of the National Health Insurance in 1995, the age-
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0e14-year-olds (Liu et al, Cancer Epidemiology, in press).
Intriguingly, the incidence of neuroblastoma in Taiwan is
lower than that in China (10.1/million in 0e14-year-olds)4
and the United States (10.4/million in 0e14-year-olds).5
Similar to other extracranial embryonal cancers, most
neuroblastoma patients are diagnosed before the age of 4
years.3 Young children, especially those younger than
1e1.5 years without MYCN amplification, usually enjoy
excellent survival.
Since the clinical course of neuroblastoma is variable, it
is mandatory to tailor the treatment plan based on prog-
nostic factors. State-of-the-art treatment protocols for
neuroblastoma usually stratify patients into four “risk
groups” based on their different risks of death or devel-
oping an event (i.e., relapse, progression, or secondary
malignancy).6 Fig. 1 shows the recent survival data from a
major tertiary hospital in Taiwan. Patients can generally be
divided into two clusters with very different outcomes: the
curable low-risk (LR) or intermediate-risk (IR) groups, and
the high-risk (HR) or ultra-high-risk (UHR) groups with a
much lower cure rate. Such a striking dichotomy not only
underscores the importance of risk-directed therapy but
also demonstrates that there are different goals of research
for each risk group.6
The LR group includes all stage 1 patients, all stage 2
infants and children with normal MYCN copy number,Association. All rights reserved.
Figure 1 Risk-directed goals for neuroblastoma therapy and
research. Kaplan-Meier curves are plotted from the survival
data of 70 patients with neuroblastoma treated at National
Taiwan University Hospital (NTUH) in Taipei, Taiwan, between
2006 and 2013. Low risk (LR), intermediate risk (IR), and high
risk (HR) are defined by age, stage, MYCN status, and histo-
pathology according to the Taiwan Pediatric Oncology Group’s
TPOG-N2002 protocol. Ultra-high risk (UHR) refers to HR pa-
tients with MYCN amplification. The concept in this figure was
inspired by a speech from Professor Angelika Eggert (University
Children’s Hospital Essen, Germany) on October 27, 2011,
entitled “State-of-the-Art in Neuroblastoma Research” and
presented at the 43rd Congress of the International Society of
Paediatric Oncology (SIOP) in Auckland, New Zealand.
888 Y.-L. Liu et al.stage 2 children with MYCN amplification and favorable
histology, and stage 4S with normal MYCN and favorable
histology. Surgical resection alone is sufficient for the
treatment of LR patients, while chemotherapy may only
be needed for symptomatic children. With the advent of
ultrasound imaging in prenatal screening, more and more
LR patients are diagnosed as an incidental finding. A sub-
set of these tumors may show spontaneous regression.
Studying LR neuroblastoma may help us to understand
more about the mechanisms of neuronal differentiation
and maturation.
The IR group includes stage 3 or 4 infants, stage 3 chil-
dren with favorable histology, and stage 4S infants with
unfavorable histology and normal MYCN. In IR patients,
gross total resection of the primary tumor, either at first
operation or after induction chemotherapy, may be of
survival benefit. Although dose-intensive chemotherapy can
achieve a high cure rate in IR, 4e8 cycles of reduced-dose
chemotherapy has been proven to be equally effective with
less toxicity.7 Long-term follow-up of these modestly
treated patients, ideally through a cancer survivorship
program, is warranted.
The HR group includes stage 2 children with MYCN
amplification and unfavorable histology, stage 3 with MYCN
amplification or unfavorable histology, stage 4 patients who
are older than 365 days or who have MYCN amplification,
and stage 4S with MYCN amplification. In addition to sur-
gery and chemotherapy, treatment for HR patients includeshigh-dose therapy with autologous stem cell trans-
plantation, radiation therapy, and 13-cis-retinoic acid. The
promising anti-GD2 immunotherapy is not yet available in
many countries outside Europe and North America, war-
ranting more international efforts. HR patients have a 5-
year survival rate of 36% (Fig. 1), indicating that a sub-
stantial proportion of patients can truly benefit from dose-
intensive regimens. Research for this group should be
directed to better risk stratification by identifying more
patients who are still at risk under current therapy. New
biomarkers and an understanding of disease mechanisms
are needed.
HR patients with MYCN amplification are designated as
UHR (Fig. 1). Even with current multimodality treatment,
most patients with UHR neuroblastoma are not curable. If
no experimental therapy is available for UHR neuroblas-
toma at relapse or progression, shifting to palliative care
should be strongly considered. On the other hand, when
frontline treatment fails in HR and UHR patients, they are
ideal candidates for innovative phase 1 or 2 clinical trials
and should not be precluded from the opportunity of
receiving novel therapies. In addition to MYCN amplifica-
tion, next-generation sequencing technologies have iden-
tified recurrent driver mutations from genes such as ALK,
PTPN11 and ATRX8 that have also become the targets of
new drug development. In the post-genomic era, more ef-
forts are needed to translate medical research into
treatment.
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